Richard E. Valocik - Concepedia

Author

Richard E. Valocik

New Frontier

Also Known As

R E Valocik, R Valocik, R.E. VALOCIK, Richard E Valocik, Richard E. Valocik, Richard Valocik

Publications

473

Citations

H-Index

Concepts

All Affiliations

New Frontier Upsher-Smith Laboratories (United Kingdom)GlaxoSmithKline (United Kingdom)GlaxoSmithKline (United States)

About

Richard E. Valocik is an author at New Frontier specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	223
2	Immunology	2	2	104
3	Social Sciences	1	1	16
4	Biochemistry	1	1	10
5	Biomedical Engineering	1	1	28

Richard E. Valocik

Publications

437

Citations

H-Index

Page 1

	Year	Citations
Antithrombotic Efficacy of a Novel Murine Antihuman Factor IX Antibody in Rats Giora Feuerstein, Arun Patel, John R. Toomey, Arteriosclerosis Thrombosis and Vascular Biology ImmunologyPathologySingle BolusPharmacotherapyBolus 15	1999	69
Effects of the leukotrienes on the vasculature and blood pressure of different species. Barry A. Berkowitz, Bogdan Zabko-Potapovich, Richard E. Valocik, Journal of Pharmacology and Experimental Therapeutics	1984	63
Inhibition of Factor IX(a) Is Protective in a Rat Model of Thromboembolic Stroke John R. Toomey, Richard E. Valocik, Paul F. Koster, Stroke	2002	52
An Inhibitory Anti-factor IX Antibody Effectively Reduces Thrombus Formation in a Rat Model of Venous Thrombosis G Feuerstein, John R. Toomey, Richard E. Valocik, Thrombosis and Haemostasis	1999	51
A comparison of the β‐D‐xyloside, odiparcil, to warfarin in a rat model of venous thrombosis John R. Toomey, Melanie A Abboud, Richard E. Valocik, Journal of Thrombosis and Haemostasis ThrombosisVenous ThrombosisBlood PlateletMedicineHematology	2006	36
Comparing the Antithrombotic Efficacy of a Humanized Anti-factor IX(a) Monoclonal Antibody (SB 249417) to the Low Molecular Weight Heparin Enoxaparin In a Rat Model of Arterial Thrombosis John R. Toomey, Michael N. Blackburn, Barbara L. Storer, Thrombosis Research ThrombosisVenous ThrombosisCardiovascular DiseaseBlood PlateletMedicine	2000	35
Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist William E. Bondinell, Richard M. Keenan, William H. Miller, Bioorganic & Medicinal Chemistry ThrombopoiesisThrombosisSignal TransductionBlood PlateletMedicine	1994	28
Demonstration of specific dopamine-1 receptor-mediated coronary vasodilation in the anesthetized dog. Gregory A. Kopia, Richard E. Valocik Journal of Pharmacology and Experimental Therapeutics	1989	20
Antithrombotic Potential of GW813893: A Novel, Orally Active, Active-site Directed Factor Xa Inhibitor Melanie A Abboud, Saul Needle, Cynthia L. Burns-Kurtis, Journal of Cardiovascular Pharmacology	2008	17
Hemodynamic Effects of Selective Dopamine Receptor Agonists in the Rat and Dog J. Paul Hieble, David Owen, Carol Harvey, Clinical and Experimental Hypertension Part A Theory and Practice NeurophysiologyMedicineHemodynamic EffectsPhysiologySelective Dopamine Receptor	1987	16

Page 1